Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.

NCT Number	NCT06358638
Lead Sponsor	Children's National Research Institute Collaborators: Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Conditions	Sickle Cell Disease
Enrollment	12 participants
Start Date	2024-04-03
Primary Completion	2044-09 (estimated)
Study Completion	2054-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-26